)
PharmaCorp Rx (PCRX) investor relations material
PharmaCorp Rx Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Revenue for Q2 2026 rose 75.8% year-over-year to $7.7 million, driven by organic growth and acquisitions.
Gross profit increased 78.2% year-over-year to $3.1 million, with gross margin improving to 40.3%.
Net income reached $0.12 million in Q2 2026, reversing a net loss of $0.39 million in Q2 2025.
Same-store sales grew 3.8% and same-store prescription sales rose 5.2% year-over-year.
Financial highlights
Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis) for Q2 2026 was $1.7 million, up 148.7% from Q2 2025.
Cash position as of June 30, 2026, was $24.0 million, compared to $25.9 million at year-end 2025.
Year-over-year improvements attributed to higher prescription volumes, front-of-store sales, and increased pharmacy ownership (six vs. three locations).
Outlook and guidance
Management highlights ongoing momentum in acquisition and integration strategy, with nine pharmacy acquisitions closed in July and another in August, bringing the total to 16 pharmacies.
Forward-looking statements emphasize continued focus on acquiring and integrating community pharmacies across Canada.
- Exclusive acquisition pipeline and integration drive scalable growth in Canadian pharmacy.PCRX
Investor presentation - Exclusive acquisition rights and integration drive scalable pharmacy growth in Canada.PCRX
Investor presentation - Q1 2026 revenue jumped 79.4% year-over-year, driven by acquisitions and organic growth.PCRX
Q1 2026 - Revenue up 75% and gross profit up 78% in Q4 2025, with strong M&A-driven growth.PCRX
Q4 2025 - Exclusive acquisition rights and integration drive scalable pharmacy growth in Canada.PCRX
Investor presentation - Pharmacy roll-up firm leverages exclusive alliances and capital to drive steady national expansion.PCRX
2026 Bloom Burton & Co. Healthcare Investor Conference - Q3 adjusted EBITDA and sales rose, with new capital and acquisitions fueling national expansion.PCRX
Q3 2025 - First profitable quarter with $254,000 net income and plans to acquire four pharmacies for $12.5M.PCRX
Q1 2025 - Q2 2025 saw 11.3% same store sales growth, $688K EBITDA, and new acquisitions fueling expansion.PCRX
Q2 2025
Next PharmaCorp Rx earnings date
Next PharmaCorp Rx earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)